← All trials
NCT03440021
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 26, 2018
- Primary completion
- Aug 31, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 69
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Cape TownLead sponsor
- Orion CorporationCollaborator
- University of OxfordCollaborator
- University of Cape TownReponsible party - principal investigator
- University of Cape TownOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.